Intestinal Motility Disorders 

  • Author: Nafisa K Kuwajerwala, MD; Chief Editor: Julian Katz, MD   more...
 
Updated: Feb 1, 2012
 

Background

The phrase intestinal motility disorders applies to abnormal intestinal contractions, such as spasms and intestinal paralysis. This phrase is used to describe a variety of disorders in which the gut has lost its ability to coordinate muscular activity because of endogenous or exogenous causes.[1, 2, 3] Such disorders may be primitive or secondary and may manifest in a variety of ways, including the following:

In a broad sense, any alteration in the transit of foods and secretions into the digestive tube may be considered an intestinal motility disorder. Such alterations would include several asymptomatic conditions, such as maldigestion, achalasia, or alkaline bile reflux from the duodenum to the stomach (and sometimes the esophagus). In a narrow sense, only the following should be considered intestinal motility disorders[4, 5] :

Chronic intestinal pseudo-obstruction (CIP) is a clinical syndrome caused by ineffective intestinal propulsion and characterized by symptoms and signs of intestinal obstruction in the absence of an occluding lesion of the intestinal lumen.[6] CIP is caused by a group of heterogeneous nerve and muscle disorders and results in obstructive intestinal symptoms in the absence of any mechanical obstruction.

A consensus working group defined CIP as a “rare, severe disabling disorder characterized by repetitive episodes or continuous symptoms and signs of bowel obstruction, including radiographic documentation of dilated bowel with air-fluid levels, in the absence of a fixed, lumen-occluding lesion.”[7] However, this definition is really applicable only to the most severe forms of CIP; air-fluid levels may not always be present.

Thus, the criteria for diagnosis should include definite symptoms and signs of obstruction, with documentation of an ileus or air-fluid levels on plain radiographs of the abdomen or a dilated duodenum, small intestine, or colon on barium radiographs. Even though severe dysmotility may otherwise be present, the term pseudo-obstruction should not be used when these radiographic findings are absent.

Next

Pathophysiology

Coordinated movements of the stomach and intestines are required to digest and propel intestinal contents along the digestive tube. The complex patterns of contraction and relaxation necessary for proper motility of the gastrointestinal (GI) tract are generated in the nerves and muscles within the GI walls.

Every day, at any time, many factors can influence GI motility (eg, physical exercise, emotional distress). The pathogenesis of primitive intestinal motility disorders probably is multifactorial, but neither biochemical abnormality nor structural abnormality has been demonstrated commonly, except in some forms of intestinal pseudo-obstruction.

Although the overall structural organization is similar throughout the digestive tube, each part has distinct motor activities. The musculature of the digestive tract has either extrinsic innervation (both sympathetic and parasympathetic) or intrinsic innervation (Auerbach plexus or myenteric plexus).

Intrinsic innervation is fundamental to coordinating GI motor activity. A neural network branching between longitudinal and circular muscle layers of the GI tract constitutes intrinsic innervation. Another nervous intrinsic plexus in the GI tract (Meissner plexus or submucosal plexus) helps to modify mucosal absorption and secretion without influencing motility.

Random, unorganized motor activity with occasional peristaltic and antiperistaltic complexes appears during feeding, and this allows gastric remixing of foods. After this, another motor activity appears during the interdigestive period. This activity is more regular and begins the peristaltic waves (ie, contractions of the circular musculature of the small intestine) that allow progression of undigested food through the intestines.

These events happen because the gastric pacemaker area, which originates electric slow waves with a frequency of 3 cycles per minute, occurs at the junction between the body and the antrum of the stomach. These electric waves, called migrating myoelectric complexes, determine the frequency of muscular contractions in the antral and pyloric areas through electromechanical coupling.

Migrating myoelectric complexes regulate gastric emptying and move gastric contents distally. Every 90 minutes, a cluster of migrating myoelectric complexes arises in the stomach and migrates distally beyond the ileum. Vagal function; the release of nitric oxide, vasoactive intestinal polypeptide, and motilin; and nutrients of the meal and other enterohormones also affect GI motility.

Knowles and Martin attempted to define a novel classification for intestinal motility disorders,[8] in which these conditions are categorized as well-defined entities, entities with a variable dysfunction-symptom relation, questionable entities, and entities associated with behavioral disorders.

Well-defined entities in the Knowles-Martin classification include the following:

  • Delayed colonic transit - Slow transit constipation (eg, enteric neuropathy, enteric myopathy, Parkinson disease, endocrine disorders, spinal injury)
  • Dilated colon (diffuse or segmental) - Ogilvie syndrome, megacolon
  • Absent rectoanal inhibitory reflex - Hirschsprung disease

Entities with a variable dysfunction-symptom relation include the following:

  • Abnormally low anal canal pressure fecal incontinence (eg, diabetes mellitus, spinal injury)

Questionable entities include the following:

  • Accelerated transit bile salts
  • Short bowel
  • Rare endocrine and metabolic disorders

Entities associated with behavioral disorders include the following:

  • Impaired pelvic floor relaxation prolonged storage in the rectosigmoid, outlet delay, anismus
  • Avoidance of defecation functional fecal retention (eg, poor pelvic floor training, poor diet, fear of pain, learned suppression)
Previous
Next

Etiology

Causes of intestinal motility disorders seem to be multifactorial, and only a few have been detected.

Degenerative disorders cause pseudo-obstruction along with other problems; however, in patients with pseudo-obstruction, only changes in the nervous and muscular systems have been observed.

Many drugs that are commonly used (eg, tricyclic antidepressants, diuretics, laxatives) or have specific indications (eg, lithium salts, vinca alkaloids, and other chemotherapy agents) may interfere with intestinal motility. Stypsis may be related to drug abuse. Drugs such as benzodiazepines, lithium salts, laxatives, and codeine cause secondary stypsis. The latter can produce narcotic bowel syndrome, which is usually observed in patients who abuse opiates for chronic pain.

Endocrine disorders (eg, myxedema) can also cause pseudo-obstruction.

IBS, the more commonly diagnosed disorder of intestinal motility, has been considered a disease of the colon for decades, but research on GI motility has demonstrated that underlying motility disturbances can occur in the small bowel.

Chronic intestinal pseudo-obstruction

Usually, CIP occurs in patients with severe comorbid clinical conditions or after traumas (even surgical) or in patients with other underlying medical diseases. In children, this condition is usually congenital and caused by a lack of ganglionic development in the intestine (Hirschsprung disease).

Irritable bowel syndrome

The causes of IBS remain unknown. According to some reports, the small intestine and colon of patients with IBS are more sensitive and reactive to mild stimuli than usual. IBS could be related to immature status of muscles and nerves in the intestinal wall of these persons.

Fecal incontinence

Aging, dementia, strokes, Parkinson disease, spinal cord injuries, rectal tears during birthing, diabetes, surgical complications, and neuromuscular disorders (eg, myasthenia gravis) may cause fecal incontinence.

Occasionally, fecal incontinence may occur after ingestion of certain foods. Sugars, insoluble fibers, and starches (except rice) are broken down in the intestines, forming a variable amount of gas that must be expelled. Most people who have lactase deficiency cannot digest lactose, a sugar common in several foods (eg, milk, cakes). People who have lactose deficiency may experience uncontrolled liquid diarrhea after lactose ingestion.

Constipation

Constipation commonly has several causes, either primitive or secondary. The most frequent of these are the following:

  • Diet that is very poor in fiber and high in animal fats and refined sugars
  • Pregnancy
  • Psychological constipation related to lifestyle changes (eg, travel, a new job, or divorce), in which the patient ignores the urge to defecate
  • Hypothyroidism
  • Electrolyte imbalance, especially if it involves Ca++ or K+
  • Tumors producing mechanical compression on an intestinal tract, either internally or externally
  • Nervous system injuries
  • Intoxication from lead, mercury, phosphorus, or arsenic
  • Constipation also may be secondary to rhagades (anal fissures) and piles.

Genetic factors

In a retrospective study investigating the association between mitochondrial disorders and CIP in 80 patients, Amiot et al determined that 15 patients (19% of the study cohort) had mitochondrial defects, including mutations in the thymidine phosphorylase gene (5 patients), the DNA polymerase-gamma gene (5 patients), and tRNA(leu(UUR)) (2 patients); 3 of the patients had no identifiable genetic defects.[9] Extradigestive symptoms occurred in all 15 patients.

Unlike other CIP patients, patients in whom the condition was associated with a mitochondrial defect tended to require frequent and long-term parenteral nutrition.[9] Because of the frequent occurrence of digestive and neurologic complications, these patients also had a high incidence of premature death. The authors suggested that mitochondrial defects are an important cause of CIP and recommended that CIP patients be tested for such defects, particularly those with severe CIP who experience associated neurologic symptoms.

Previous
Next

Epidemiology

According to some epidemiologic reports, as many as 30 million Americans have intestinal motility disorders. Available data from the medical literature indicate that worldwide, 30-45% of all GI conditions are referable to intestinal motility disorders.

When intestinal motility disorders are idiopathic and not related to either malignancies or systemic diseases, morbidity is minimal and mortality from complications is low (1-1.5%); complications usually occur in patients with intestinal pseudo-obstruction.

Persons of any age group may be affected, depending on the specific intestinal motility disorder. For example, IBS occurs more frequently in people aged 20-40 years, whereas intestinal pseudo-obstruction may occur in either newborns or elderly patients. Most patients are female, with a female-to-male ratio of 2.8:1. Primitive intestinal motility disorders are most common in white persons and are usually thought to be related to diet.

Previous
Next

Prognosis

Intestinal motility disorders that are primitive or not secondary to malignancy or debilitating pathology have a good prognosis. According to many reports, the prognosis is excellent for patients with IBS, uncomplicated primitive constipation, and mild fecal incontinence.

The prognosis is worse for patients with intestinal pseudo-obstruction, which has a high mortality.

Previous
 
 
Contributor Information and Disclosures
Author

Nafisa K Kuwajerwala, MD  Staff Surgeon, Breast Care Center, William Beaumont Hospital

Nafisa K Kuwajerwala, MD is a member of the following medical societies: American College of Surgeons, American Society of Breast Disease, and American Society of Breast Surgeons

Disclosure: Nothing to disclose.

Coauthor(s)

Venkata Subramanian Kanthimathinathan, MD  Staff Physician, Department of General Surgery, Loma Linda University Medical Center

Disclosure: Nothing to disclose.

Luigi Santacroce, MD  Assistant Professor, Medical School, State University at Bari, Italy

Disclosure: Nothing to disclose.

Vivek V Gumaste, MD  Associate Professor of Medicine, Mount Sinai School of Medicine of New York University; Adjunct Clinical Assistant, Mount Sinai Hospital; Director, Division of Gastroenterology, City Hospital Center

Vivek V Gumaste, MD is a member of the following medical societies: American College of Gastroenterology and American Gastroenterological Association

Disclosure: Nothing to disclose.

Chief Editor

Julian Katz, MD  Clinical Professor of Medicine, Drexel University College of Medicine

Julian Katz, MD is a member of the following medical societies: American College of Gastroenterology, American College of Physicians, American Gastroenterological Association, American Geriatrics Society, American Medical Association, American Society for Gastrointestinal Endoscopy, American Society of Law, Medicine & Ethics, American Trauma Society, Association of American Medical Colleges, and Physicians for Social Responsibility

Disclosure: Nothing to disclose.

Additional Contributors

Silvia Gagliardi, MD Consulting Staff, Department of Surgery, Medical Center Vita, Italy

Disclosure: Nothing to disclose.

Douglas M Heuman, MD, FACP, FACG, AGAF Chief of GI, Hepatology, and Nutrition at North Shore University Hospital/Long Island Jewish Medical Center; Professor, Department of Medicine, Hofstra North Shore-LIJ School of Medicine

Douglas M Heuman, MD, FACP, FACG, AGAF is a member of the following medical societies: American Association for the Study of Liver Diseases, American College of Physicians, and American Gastroenterological Association

Disclosure: Novartis Grant/research funds Other; Bayer Grant/research funds Other; Otsuka Grant/research funds None; Bristol Myers Squibb Grant/research funds Other; Scynexis None None; Salix Grant/research funds Other; MannKind Other

Sandeep Mukherjee, MB, BCh, MPH, FRCPC Associate Professor, Department of Internal Medicine, Section of Gastroenterology and Hepatology, University of Nebraska Medical Center; Consulting Staff, Section of Gastroenterology and Hepatology, Veteran Affairs Medical Center

Sandeep Mukherjee, MB, BCh, MPH, FRCPC is a member of the following medical societies: Royal College of Physicians and Surgeons of Canada

Disclosure: Merck Honoraria Speaking and teaching; Ikaria Pharmaceuticals Honoraria Board membership

Shivkumar Prabhu, MD Consulting Staff, Department of Internal Medicine, St John Detroit Riverview Hospital

Disclosure: Nothing to disclose.

Daniel Schafer Department of Surgery, University of Nebraska Medical Center

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Medscape Salary Employment

References
  1. Di Lorenzo C, Youssef NN. Diagnosis and management of intestinal motility disorders. Semin Pediatr Surg. Feb 2010;19(1):50-8. [Medline].

  2. Keller J, Layer P. Intestinal and anorectal motility and functional disorders. Best Pract Res Clin Gastroenterol. 2009;23(3):407-23. [Medline].

  3. Venkatasubramani N, Sood MR. Motility disorders of the gastrointestinal tract. Indian J Pediatr. Oct 2006;73(10):927-30. [Medline].

  4. Ouyang A, Locke GR 3rd. Overview of neurogastroenterology-gastrointestinal motility and functional GI disorders: classification, prevalence, and epidemiology. Gastroenterol Clin North Am. Sep 2007;36(3):485-98, vii. [Medline].

  5. Rao SS. Constipation: evaluation and treatment of colonic and anorectal motility disorders. Gastroenterol Clin North Am. Sep 2007;36(3):687-711, x. [Medline].

  6. De Giorgio R, Cogliandro RF, Barbara G, Corinaldesi R, Stanghellini V. Chronic intestinal pseudo-obstruction: clinical features, diagnosis, and therapy. Gastroenterol Clin North Am. Dec 2011;40(4):787-807. [Medline].

  7. Rudolph CD, Hyman PE, Altschuler SM, Christensen J, Colletti RB, Cucchiara S, et al. Diagnosis and treatment of chronic intestinal pseudo-obstruction in children: report of consensus workshop. J Pediatr Gastroenterol Nutr. Jan 1997;24(1):102-12. [Medline].

  8. Knowles CH, Martin JE. Slow transit constipation: a model of human gut dysmotility. Review of possible aetiologies. Neurogastroenterol Motil. Apr 2000;12(2):181-96. [Medline].

  9. Amiot A, Tchikviladze M, Joly F, et al. Frequency of mitochondrial defects in patients with chronic intestinal pseudo-obstruction. Gastroenterology. Jul 2009;137(1):101-9. [Medline].

  10. Li B, Wang JR, Ma YL. Bowel sounds and monitoring gastrointestinal motility in critically ill patients. Clin Nurse Spec. Jan 2012;26(1):29-34. [Medline].

  11. Remes-Troche JM, Rao SS. Diagnostic testing in patients with chronic constipation. Curr Gastroenterol Rep. Oct 2006;8(5):416-24. [Medline].

  12. Maqbool S, Parkman HP, Friedenberg FK. Wireless capsule motility: comparison of the SmartPill GI monitoring system with scintigraphy for measuring whole gut transit. Dig Dis Sci. Oct 2009;54(10):2167-74. [Medline].

  13. Burns AJ. Disorders of interstitial cells of Cajal. J Pediatr Gastroenterol Nutr. Dec 2007;45 Suppl 2:S103-6. [Medline].

  14. He CL, Burgart L, Wang L, Pemberton J, Young-Fadok T, Szurszewski J, et al. Decreased interstitial cell of cajal volume in patients with slow-transit constipation. Gastroenterology. Jan 2000;118(1):14-21. [Medline].

  15. Pardi DS, Miller SM, Miller DL, Burgart LJ, Szurszewski JH, Lennon VA, et al. Paraneoplastic dysmotility: loss of interstitial cells of Cajal. Am J Gastroenterol. Jul 2002;97(7):1828-33. [Medline].

  16. Sanders KM. Interstitial cells of Cajal at the clinical and scientific interface. J Physiol. Nov 1 2006;576(Pt 3):683-7. [Medline].

  17. Cleveland Clinical Foundation, Center for Gastrointestinal Motility Disorders. Intestinal motility disorders. Available at: http://www.ccf.org/gastro/motility/default.htm. Cleveland, Ohio: Cleveland Clinic;. 1999. [Full Text].

  18. Fu A. Neostigmine: an alternative treatment for constipation. Dynamics. 2005;16(1):13-5. [Medline].

  19. Karamanolis G, Tack J. Promotility medications--now and in the future. Dig Dis. 2006;24(3-4):297-307. [Medline].

  20. Sarna SK. Molecular, functional, and pharmacological targets for the development of gut promotility drugs. Am J Physiol Gastrointest Liver Physiol. Oct 2006;291(4):G545-55. [Medline].

  21. Quigley EM. Prucalopride: safety, efficacy and potential applications. Therap Adv Gastroenterol. Jan 2012;5(1):23-30. [Medline]. [Full Text].

  22. Mazzone A, Farrugia G. Evolving concepts in the cellular control of gastrointestinal motility: neurogastroenterology and enteric sciences. Gastroenterol Clin North Am. Sep 2007;36(3):499-513, vii. [Medline].

  23. Sigurdsson L, Reyes J, Kocoshis SA, et al. Intestinal transplantation in children with chronic intestinal pseudo- obstruction. Gut. Oct 1999;45(4):570-4. [Medline].

  24. Millar AJ, Gupte G, Sharif K. Intestinal transplantation for motility disorders. Semin Pediatr Surg. Nov 2009;18(4):258-62. [Medline].

Previous
Next
 
Dilated cecum (16 cm) and colon in patient with pseudocolonic obstruction.
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2012 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.